Published in Breast Cancer Res Treat on June 14, 2015
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors | NCT01273168
Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator. ACS Med Chem Lett (2016) 0.75
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed (2010) 3.51
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther (2013) 3.11
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther (2011) 2.09
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94
Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res (1989) 1.91
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos (2007) 1.48
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res (1988) 1.45
Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther (2011) 1.39
Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res (1991) 1.36
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat (2009) 1.34
Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos (1982) 1.30
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia (2010) 1.15
Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther (2010) 1.14
CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci (2007) 1.09
Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos (2007) 1.06
Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep (1981) 1.03
Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat (2010) 1.00
Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response. Eur J Cancer (1980) 0.90
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat (2013) 0.84
Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat (2014) 0.83
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell (2007) 5.49
Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell (2008) 5.04
Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science (2013) 4.94
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Genome sequencing reveals insights into physiology and longevity of the naked mole rat. Nature (2011) 3.19
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
The use and interpretation of competing risks regression models. Clin Cancer Res (2012) 3.01
The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat Nanotechnol (2011) 2.98
Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med (2012) 2.90
Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater (2009) 2.85
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol (2005) 2.81
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Groundwater arsenic contamination throughout China. Science (2013) 2.64
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med (2004) 2.64
The HIV epidemic in Yunnan Province, China, 1989-2007. J Acquir Immune Defic Syndr (2010) 2.61
Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes (2007) 2.59
Targeting Notch to target cancer stem cells. Clin Cancer Res (2010) 2.46
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Controlling the synthesis and assembly of silver nanostructures for plasmonic applications. Chem Rev (2011) 2.40
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A (2007) 2.34
In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano (2010) 2.29
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res (2008) 2.19
Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol (2009) 2.19
Energy policy: A low-carbon road map for China. Nature (2013) 2.18
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene (2003) 2.16
Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med (2005) 2.15
Patellar resurfacing versus nonresurfacing in total knee arthroplasty: a meta-analysis of randomised controlled trials. Int Orthop (2013) 2.13
Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leukoc Biol (2003) 2.08
The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci (2003) 2.05
Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res (2010) 2.04
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. Nature (2010) 2.02
The extended distally based sural neurocutaneous flap for foot and ankle reconstruction: a retrospective review of 10 years of experience. Ann Plast Surg (2014) 2.00
Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res (2003) 1.98
Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet (2013) 1.95
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS One (2010) 1.92
Gold nanocages as photothermal transducers for cancer treatment. Small (2010) 1.92
De novo assembly and characterisation of the transcriptome during seed development, and generation of genic-SSR markers in peanut (Arachis hypogaea L.). BMC Genomics (2012) 1.90
Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res (2007) 1.88
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. Structure (2008) 1.86
Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med (2006) 1.82
Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci (2002) 1.80
Gold nanocages: from synthesis to theranostic applications. Acc Chem Res (2011) 1.80
Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med (2002) 1.79
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2012) 1.77
Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A (2004) 1.77
Human cytomegalovirus expresses novel microRNAs during productive viral infection. Cell Microbiol (2005) 1.76
TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol (2003) 1.75
Reduction of transient signal oscillations in true-FISP using a linear flip angle series magnetization preparation. Magn Reson Med (2003) 1.73
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood (2008) 1.69
China's international trade and air pollution in the United States. Proc Natl Acad Sci U S A (2014) 1.66
ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol (2009) 1.63
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer (2008) 1.63
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 1.63
St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol (2006) 1.60
Versatile synthesis strategy for carboxylic acid-functionalized upconverting nanophosphors as biological labels. J Am Chem Soc (2008) 1.56
Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 1.55
Solution structure of the MAPK phosphatase PAC-1 catalytic domain. Insights into substrate-induced enzymatic activation of MKP. Structure (2003) 1.54
In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity. Int J Pharm (2012) 1.54
CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry (2006) 1.54
Automated rectilinear self-gated cardiac cine imaging. Magn Reson Med (2004) 1.52
Retracted GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. PLoS One (2012) 1.52
Genetic evolution of swine influenza A (H3N2) viruses in China from 1970 to 2006. J Clin Microbiol (2008) 1.52
Satellite-Based Spatiotemporal Trends in PM2.5 Concentrations: China, 2004-2013. Environ Health Perspect (2015) 1.51
Projections of global mercury emissions in 2050. Environ Sci Technol (2009) 1.51
The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small (2010) 1.50
Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect (2010) 1.47
Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem (2011) 1.43
Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol (2003) 1.43
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci (2009) 1.42
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther (2004) 1.40
A nonhuman primate model of lung regeneration: detergent-mediated decellularization and initial in vitro recellularization with mesenchymal stem cells. Tissue Eng Part A (2012) 1.39
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res (2011) 1.38
Introducing the external link model for studying spine fixation and misalignment: part 1--need, rationale, and applications. J Manipulative Physiol Ther (2007) 1.38
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood (2004) 1.38
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release (2009) 1.38
The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate (2008) 1.38
Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res (2010) 1.37
Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res (2002) 1.36
Schiff base transition metal complexes as novel inhibitors of xanthine oxidase. Eur J Med Chem (2007) 1.36
Involvement of notch signaling in wound healing. PLoS One (2007) 1.35
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol (2008) 1.34
CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest (2005) 1.33
The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem (2007) 1.33
γ-Secretase inhibitors and modulators. Biochim Biophys Acta (2013) 1.32
A three-dimensional carbon nanotube/graphene sandwich and its application as electrode in supercapacitors. Adv Mater (2010) 1.31
The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol (2002) 1.30
Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res (2008) 1.30
MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog (2013) 1.29
Modeling regional/urban ozone and particulate matter in Beijing, China. J Air Waste Manag Assoc (2009) 1.29